Xenon Pharmaceuticals Q3 Earnings Call Highlights

Key Points

• Depression trial results are expected in December, earlier than previously forecast, after enrollment completed in the phase III X-NOVA2 study. Xenon will review efficacy and safety findings with the monitoring board and FDA before deciding whether to continue AZK’s psychiatric development; enrollment in related studies was paused after neuropsychiatric adverse events were reviewed.
• Xenon submitted an FDA application for AZK in focal seizures and is preparing for a potential U.S. launch, though approval is not yet assured. It also plans to begin a phase IIIb/IV study in early 2027 and is building commercial and payer infrastructure.
• Two pain candidates are expected to enter phase II testing in the first half of 2027. Xenon reported $1.2 billion in cash, equivalents and marketable securities, which it expects to fund operations into 2029.

Xenon Pharmaceuticals NASDAQ: XENE expects pivotal depression study results in December, earlier than previously projected, while preparing for a potential U.S. launch of its lead epilepsy drug and advancing two pain treatments into midstage testing.

On its third-quarter 2026 earnings call, the company said it had completed enrollment in the phase III X-NOVA2 trial of azetukalner, or AZK, in major depressive disorder. The results are expected to help Xenon decide how to proceed with its broader psychiatric program after it voluntarily paused new patient enrollment in September.

Separately, Xenon submitted a new drug application to the Food and Drug Administration in the third quarter seeking approval of AZK for focal seizures. The company is building commercial infrastructure ahead of a potential launch, although the drug has not yet been approved.

Depression data to guide next steps

X-NOVA2 randomized approximately 360 patients, and Xenon now expects top-line results in December rather than the first quarter of 2027. Chief Medical Officer Chris Kenney said the study is designed to assess the drug’s effect on depression symptoms at six weeks.

The earlier enrollment pause followed a review with the study’s data safety monitoring board of neuropsychiatric adverse events in the major depressive disorder and bipolar depression studies. Kenney said the events were mostly mild or moderate and were consistent in number and severity with AZK’s known profile in epilepsy, but had not been observed in the earlier phase II depression study.

Kenney said Xenon plans to share the unblinded results and its proposal for proceeding with the monitoring board, then meet with the FDA. The company did not provide a timeline for implementing potential protocol changes.

Chief Executive Officer Ian Mortimer said the company would assess both efficacy and safety before deciding whether to continue developing AZK in psychiatry. “If the data do not support future development, then we will cross that bridge when we get there,” he said.

In addition to the primary depression endpoint, Mortimer said Xenon expects to report a key secondary measure of anhedonia—the reduced ability to experience pleasure—and information on the unblinded safety profile.

Epilepsy launch preparations and new study

Xenon’s FDA submission is supported by the phase IIb X-TOLE and phase III X-TOLE2 studies. Mortimer said all four AZK doses tested across the studies produced statistically significant reductions in monthly seizure frequency from baseline compared with placebo. In X-TOLE2, the placebo-adjusted median percentage change was 42.7%.

Mortimer said AZK was generally well tolerated across the pivotal and open-label extension studies. Xenon’s epilepsy program has accumulated more than 1,500 patient-years of safety and exposure data, he said.

The company also plans to start a U.S. phase IIIb/IV study called X-FIRST in the first quarter of 2027. The open-label study will assess AZK as a first add-on treatment for patients with a lower seizure burden than those in the earlier pivotal trials. It will include a 52-week treatment period and examine seizure reduction and periods of seizure freedom, among other endpoints.

Chief Commercial Officer Darren Cline said Xenon is nearing selection of a specialty pharmacy network and plans to deploy a field payer team early in 2027. He cautioned that broad insurance coverage would take time after commercial availability.

Pain candidates move toward phase II

Xenon expects to initiate phase II proof-of-concept studies in acute pain in the first half of 2027 for XEN1701, which targets NaV1.7, and XEN1120, which targets Kv7. The company is finalizing study designs and plans to provide more information as the trials get underway.

Kenney said phase I testing of XEN1701 in healthy volunteers showed, through drug sampling and receptor occupancy modeling, that proposed phase II doses achieved and maintained more than 75% NaV1.7 receptor occupancy in the peripheral and central nervous systems with twice-daily dosing. He also cited pain-model results in nonhuman primates using a representative inhibitor.

There were no treatment-related dose-limiting adverse events, serious treatment-emergent adverse events or adverse events leading to discontinuation in the XEN1701 study, Kenney said. Asked about a participant who experienced syncope, he said the person had some orthostatic hypotension at baseline and that he was not convinced the event was drug-related.

For XEN1120, Kenney said phase I drug exposures exceeded levels predicted to be effective based on preclinical models. The candidate was generally well tolerated, he said, with no treatment-related dose-limiting adverse events, serious or severe adverse events, or adverse events leading to discontinuation.

Cash runway

Chief Financial Officer Tucker Kelly said Xenon entered the third quarter with $1.2 billion in cash, equivalents and marketable securities. Based on current operating plans, the company expects that funding to support operations into 2029.

Kelly said the balance sheet would support preparations for AZK’s potential U.S. launch, additional registration programs and advancement of the pain candidates. He referred investors to Xenon’s press release and quarterly filing for further financial details.

About Xenon Pharmaceuticals (NASDAQ:XENE)

Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for neurological disorders. The company's research emphasizes ion channels, proteins that help regulate the electrical activity of nerve cells.

Its lead program is azetukalner, formerly known as XEN1101, an oral Kv7 potassium-channel opener being developed for seizure disorders, including focal epilepsy. Xenon is also advancing other drug candidates aimed at neurological conditions.

Founded in 1996, Xenon is headquartered in Burnaby, British Columbia, and conducts drug development activities in North America.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.